Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study - PubMed
3 hours ago
- #Neurocognitive outcomes
- #Semaglutide
- #Tirzepatide
- Study compares tirzepatide and semaglutide for preventing mild cognitive impairment (MCI), dementia, and Alzheimer's disease (AD) in type 2 diabetes patients.
- Retrospective cohort study using electronic health records from the TriNetX research network, with propensity score matching to balance baseline characteristics.
- Tirzepatide associated with lower risk of MCI (RR 0.12), dementia (RR 0.15), and AD (RR 0.48) compared to semaglutide.
- Absolute risks for all outcomes were low, with more consistent results for MCI than dementia or AD.
- Findings suggest tirzepatide may have neuroprotective benefits but require further validation via prospective randomized trials.